Distressing adverse events after antidepressant switch in the sequenced treatment alternatives to relieve depression (STAR*D) trial: Influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant

Pharmacotherapy

Volumn 32, Issue 3, 2012, Pages 234-243

  Katz, Aaron J ^a   Dusetzina, Stacie B ^b   Farley, Joel F ^a   Ellis, Alan R ^c   Gaynes, Bradley N ^d   Castillo, Wendy C ^e   Stürmer, Til ^e   Hansen, Richard A ^f  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e University of North Carolina at Chapel Hill   (United States)

^f NONE

Author keywords

Adverse events; Antidepressants; Depression; Medical switching

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; SERTRALINE; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EAR DISEASE; ENERGY; EYE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING DISORDER; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALAISE; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MENTAL HEALTH CARE; NEUROLOGIC DISEASE; OUTPATIENT; POOR CONCENTRATION; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; UROGENITAL TRACT DISEASE; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG SUBSTITUTION; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864580773     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2011.01020.x     Document Type: Article

References (40)

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62(6):593-602.
2. Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and men in the NHANES I study. National Health and Nutrition Examination Survey. Arch Intern Med 2000;160(9): 1261-8.
3. Wulsin LR, Vaillant GE, Wells VE. A systematic review of the mortality of depression. Psychosom Med 1999;61(1):6-17.
4. Unutzer J, Patrick DL, Marmon T, Simon GE, Katon WJ. Depressive symptoms and mortality in a prospective study of 2,558 older adults. Am J Geriatr Psychiatry 2002;10(5): 521-30.
5. McCusker J, Cole M, Ciampi A, Latimer E, Windholz S, Belzile E. Does depression in older medical inpatients predict mortality? J Gerontol A Biol Sci Med Sci 2006;61(9):975-81.
6. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry 2003;64 (12):1465-75.
7. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66(8): 848-56.
8. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143(6):415-26.
9. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med 2008;149(10):734-50.
10. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006;163(1):28-40.
11. Corey-Lisle PK, Nash R, Stang P, Swindle R. Response, partial response, and nonresponse in primary care treatment of depression. Arch Intern Med 2004;164(11):1197-204.
12. O'Connor EA, Whitlock EP, Beil TL, Gaynes BN. Screening for depression in adult patients in primary care settings: A systematic evidence review. Ann Intern Med 2009;151(11): 793-803.
13. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006;163(11):1905-17.
14. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: A double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000;20(2):122-8.
15. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991;52(8):329-35.
16. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21(4):643-58.
17. Coleman CC, King BR, Bolden-Watson C, et al. A placebocontrolled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23 (7):1040-58.
18. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: A placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11(4): 205-15.
19. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287(5):622-7.
20. Zarate CA, Kando JC, Tohen M, Weiss MK, Cole JO. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? J Clin Psychiatry 1996;57 (2):67-71.
21. Thase ME, Ferguson JM, Lydiard RB, Wilcox CS. Citalopram treatment of paroxetine-intolerant depressed patients. Depress Anxiety 2002;16(3):128-33.
22. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58(1):16-21.
23. Calabrese JR, Londborg PD, Shelton MD, Thase ME. Citalopram treatment of fluoxetine-intolerant depressed patients. J Clin Psychiatry 2003;64(5):562-7.
24. Brown WA, Harrison W. Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? J Clin Psychiatry 1995;56(1):30-4.
25. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design. Control Clin Trials 2004;25(1):119-42.
26. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009;166 (5):599-607.
27. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23): 3095-105.
28. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54(5):573-83.
29. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
30. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6(4):278-96.
31. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996;34(3):220-33.
32. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure. Psychopharmacol Bull 1993;29(2):321-6.
33. Graham JW. Missing data analysis: Making it work in the real world. Annu Rev Psychol 2009;60:549-76.
34. Allison PD. Missing data. Thousand Oaks, CA: Sage, 2002.
35. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159(7):702-6.
36. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry 2004;6 (4):159-66.
37. Wyeth Pharmaceuticals, Inc. Effexor XR (venlafaxine) package insert. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, 2009.
38. GlaxoSmithKline. Wellbutrin SR (bupropion hydrochloride) package insert. Research Triangle Park, NC: GlaxoSmithKline, 2007.
39. Pfizer. Zoloft (sertraline) package insert. New York, NY: Pfizer, 2008.
40. Ciraulo DA, Tsirulnik-Barts L, Shader RI, Greenblatt DJ. Clinical pharmacology and therapeutics of antidepressants. In: Ciraulo DA, Shader RI, eds. Pharmacotherapy of depression. Totowa, NJ: Humana Press, 2004: 33-119.